We are live on ! Find out more
CODX

Co-Diagnostics
CODX

86 hedge funds and large institutions have $129M invested in Co-Diagnostics in 2020 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

695% more capital invested

Capital invested by funds: $16.3M → $129M (+$113M)

456% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 9

91% more funds holding

Funds holding: 45 → 86 (+41)

81% more call options, than puts

Call options by funds: $32.4M | Put options by funds: $17.8M

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

15.93% more ownership

Funds ownership: 8.4% → 24.33% (+16%)

Holders
86
Holders Change
+41
Holders Change %
+91.11%
% of All Funds
1.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
50
Increased
18
Reduced
11
Closed
9
Calls
$32.4M
Puts
$17.8M
Net Calls
+$14.5M
Net Calls Change
+$10.9M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$27.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$7.99M
3
State Street
State Street
Massachusetts
+$7.24M
4
Northern Trust
Northern Trust
Illinois
+$4.37M
5
Nuveen
Nuveen
North Carolina
+$3.39M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$3.07M
2
Millennium Management
Millennium Management
New York
-$1.1M
3
Jane Street
Jane Street
New York
-$1.03M
4
WA
Wealth Architects
California
-$305K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$301K

CODX Hedge Fund Activity: Q2 2020 in Review

86 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q2 2020, worth a combined $129M — up 695% from $16.3M a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new CODX positions and 9 closed out — a net gain of 41 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $27.4M. The largest seller was Morgan Stanley, cutting an estimated $3.07M.

  • 86 institutional investors held Co-Diagnostics (CODX) as of Q2 2020, up from 45 in Q1 2020.
  • Funds reported $129M of Co-Diagnostics stock for Q2 2020, up 695% quarter-over-quarter.
  • 50 funds opened new Co-Diagnostics positions in Q2 2020 and 9 closed out, a net change of +41 holders.
  • The largest Co-Diagnostics buyer in Q2 2020 was BlackRock, an estimated $27.4M added.
  • The largest Co-Diagnostics seller in Q2 2020 was Morgan Stanley, an estimated $3.07M sold.

Based on aggregated 13F filings for Q2 2020.